When it comes to the FIELD study, what is...is
|
|
- Brianna Weaver
- 5 years ago
- Views:
Transcription
1 Future Lipidology ISSN: (Print) (Online) Journal homepage: When it comes to the FIELD study, what is...is James McKenney To cite this article: James McKenney (2006) When it comes to the FIELD study, what is...is, Future Lipidology, 1:3, To link to this article: Copyright 2006 Future Medicine Ltd Published online: 18 Jan Submit your article to this journal Article views: 92 Full Terms & Conditions of access and use can be found at
2 PRIORITY PAPER EVALUATION When it comes to the FIELD study, what is...is James M McKenney Virginia Commonwealth University, National Clinical Research, 2809 Emerywood Parkway, Suite 140, Richmond, VA 23294, USA Tel.: ; Fax: ; jmckenney@ncrinc.net Keywords: CHD risk, outcome studies, pharmacotherapy, risk benefit decisions, Type2diabetes Evaluation of: The FIELD Investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, (2005). The presentation of the fenofibrate intervention and event lowering in diabetes (FIELD) study last November at the American Heart Association s Annual Scientific Meeting and the subsequent publication in the Lancet represent a seminal moment in the life of fenofibrate and perhaps the entire class of fibrate lipid altering agents. The reaction to the findings of this study was at least disappointing if not worrying. How do we interpret these results? What do they teach us? How should they be applied to the care of diabetic patients, or any dyslipidemic patient for that matter? How do we make decisions regarding which triglyceride lowering agent to use, fenofibrate, gemfibrozil or niacin? Given the results of FIELD, should we be using fenofibrate at all? It shall be the goal of this commentary to critically review the findings of this pivotal study, to glean as much understanding from it as possible and to determine the implications of the study to health professionals and patients. The FIELD study results The fenofibrate intervention and event lowering in diabetes (FIELD) study was a 5-year multicenter, randomized, placebo controlled, two-arm parallel study in 9795 patients with Type 2 diabetes mellitus testing the hypothesis that long-term treatment with fenofibrate will reduce coronary morbidity and mortality [1]. Patients were required to have an initial plasma total cholesterol between 116 and 252 mg/dl ( mmol/l) and either a total cholesterol high-density lipoprotein cholesterol (HDL-C) ratio of at least 4.0 or a plasma triglyceride between 89 and 442 mg/dl ( mmol/l). Patients were not to be taking lipid-lowering drug therapy, including a statin, at study entry. Those with impaired renal function, chronic liver disease or symptomatic gallbladder disease were excluded. These criteria resulted in a study patient population that was 63% male with a mean age of 63 years and the following mean lipid profile: total cholesterol 195 mg/dl (5.03 mmol/l), HDL-C 43 mg/dl (1.10 mmol/l), low-density lipoprotein cholesterol (LDL-C) 119 mg/dl (3.07 mmol) and triglycerides 153 mg/dl (1.73 mmol/l). The investigators reported that approximately half (52%) had a triglyceride level above 150 mg/dl (1.7 mmol/l) and approximately half (59%) had a HDL-C less than 40 mg/dl (<1.03 mmol/l) if male or 50 mg/dl (<1.29 mmol/l) if female. Few (9%) smoked, 56% had hypertension (mean blood pressure [BP] of the population was 140/82 mmhg) and 22% had a prior history of cardiovascular disease (CVD). All patients meeting entrance criteria completed a 4-week dietary modification period, followed by a 6-week single-blind placebo treatment period and a 6-week single-blind fenofibrate 200 mg/day treatment period; 408 patients were dropped during the active run-in period for unclear reasons. A total of 9795 patients were randomized to fenofibrate 200 mg/day or matching placebo with breakfast and were followed at 4 6 month intervals for 5 years. Importantly, their primary care physician was at liberty to adjust usual care treatments, including the addition of lipid-altering drug therapy, during the course of the study. The primary study outcome, coronary heart disease (CHD), death and nonfatal myocardial infarction (MI), was reduced 11% (hazard ratio [HR] 0.89 [ ]; p = 0.16) (Table 1). This outcome occurred in 6% of placebo-treated patients and 5% of fenofibrate-treated patients during the 5-year study. Nonfatal MI alone was reduced 24% (HR 0.76 [ ]; p = 0.01). Some of the secondary outcomes were reduced significantly with fenofibrate, including a composite end point termed total cardiovascular (CV) events (i.e., CV death, nonfatal MI, stroke and revascularization procedures), coronary revascularization and all revascularizations (Table 1). Stroke was not reduced significantly (p = 0.36). Based on these results, 70 patients would have to be treated for 5 years with fenofibrate 200 mg/day to prevent one or more CV events in one patient. The reduction in total CV events with fenofibrate was not significantly / Future Medicine Ltd ISSN Future Lipidol. (2006) 1(3),
3 PRIORITY PAPER EVALUATION McKenney different in subjects with triglycerides levels above or below 150 mg/dl, HDL-C above or below 40 mg/dl in men, above or below 50 mg/dl in women, with or without hypertension or with or without the metabolic syndrome. Total CV events were reduced significantly in patients with no prior history of CV disease (19%; p = 0.001) but not in those with a prior CV history (p = 0.85). Total mortality, CV mortality and CHD mortality increased 11 19%; none of these s reached statistical significance. In summary, as the title of this commentary suggests, what is, is. Treatment with fenofibrate for 5 years in a huge population of CHD risk equivalent Type 2 diabetic patients, failed to produce a significant reduction in CHD death and nonfatal MI, the benchmark outcome used as the primary outcome measure in practically all of the statin trials. It did demonstrate a significant reduction in total CV events, but only in patients with no prior CHD history. It was also associated with increasing rates of total, CV and CHD mortality, which, while statistically insignificant, did not trend lower. Some explanations for study results So what went wrong? The investigators point their blame, with good reason, at the initiation of nonstudy lipid-lowering therapy during the study [1]. Of patients allocated to fenofibrate 19% (944 of 4895), and 36% of patients allocated to placebo (1776 of 4900) started other lipid lowering therapy during the course of the study. In approximately 93% of cases, this other therapy was a statin. The initiation of other lipid-lowering therapy was more likely to occur in patients receiving placebo, in those with prior CHD history and in those with higher total and LDL-C levels (apparently, the patients primary care physicians were not prohibited from obtaining lipid profiles during the study nor were they blinded to these results, a usual requirement in outcome trials). When the other lipid-lowering therapy was started, 26% of placebo patients and 38% of fenofibrate patients discontinued their assigned study drug. In other words, drop-out study treatment and drop-in other treatment was not balanced between study arms and the drop-in treatment, it appeared to be selectively started in those with highest CHD risk and highest cholesterol levels. In this manner, the integrity of the random allocation of blinded treatments in FIELD was irrevocably jeopardized, thus destroying the homogeneity of study treatment arms and the tenets upon which standard statistical evaluations are based. The authors did conduct a prespecified analysis, which adjusted for the new lipid treatments and found that fenofibrate was associated with a significant 19% reduction in CHD events (p = 0.01) and a 15% reduction in total CV events (p = 0.004). They warn, however, that due to the nonrandomized comparison, these results should be interpreted cautiously. How does FIELD compare with other fibrate outcome trials? One of the first observations one can make regarding the FIELD study, in comparison with other fibrate outcome trials, is that the s in lipid levels during the course of the study were not typical (Table 2). LDL-C levels were reduced initially by 12% (at 4 months) but only 6% by Table 1. Results of the FIELD study. Placebo (n = 4900) Fenofibrate (n = 4895) Hazard ratio (+ 95% CI, p value) Primary outcomes Coronary events 288 (6%) 256 (5%) 0.89 ( , p = 0.16) CHD mortality 93 (2%) 110 (2%) 1.19 ( , p = 0.22) Nonfatal MI 207 (4%) 158 (3%) 0.76 ( , p = 0.01) Secondary outcomes Total CV disease 683 (14%) 612 (13%) 0.89 ( , p = 0.035) CV mortality 127 (3%) 140 (3%) 1.11 ( , p = 0.41) Total mortality 323 (7%) 356 (7%) 1.11 ( , p = 0.18) Total stroke 175 (4%) 158 (3%) 0.90 ( , p = 0.43) Coronary revascularizations 364 (7%) 290 (6%) 0.79 ( , p = 0.003) All revascularizations 471 (10%) 380 (8%) 0.80 ( , p = 0.001) CHD: Coronary heart disease; CI: Confidence interval; CV: Cardiovascular; FIELD: Fenofibrate and event lowering in diabetes; MI: Myocardial infarction. 276 Future Lipidol. (2006) 1(3)
4 When it comes to the FIELD study, what is...is PRIORITY PAPER EVALUATION Table 2. Fibrate outcome studies. Study N Rx T. Chol mean FIELD 9795 F 195 (-7%) DIAS 418 F 216 (-10%) HHS 4081 G 270 (-8%) VA-HIT 2531 G 175 (-4%) BIP 3090 B 212 WHO Study CDP 3892 C 250 (-6.4%) LDL-C mean 119 (-6%) 131 (-6%) 189 (-8%) 112 (0%) 148 HLD-C mean 43 (+1%) 39 (8%) 47 (11%) 32 (6%) 35 (18%) TG mean 153 (-22%) 222 (-28%) 175 (-35%) 160 (-31%) 145 (-21%) Relative in CHD events -11% p= % -34% p< % p= % p=0.26 C (-9%) -20% p < (-16%) -7% (NS) 0% (NS) Relative in total mortality 11% p = % 7% -11% p = % (p = 0.62) +27.6% (p <0.05) Relative in CHD mortality 19% p = 0.22 Ref. [1] NR [2] -26% [3] -22% p = % (p = 0.61) +12.5% (p >0.05) -8% (NS) B: Bezafibratre; BIP: Bezafibrate infarction prevention; C: Clofibrate; CDP: Chemo/dietary prevention; DIAS: Diabetes atherosclerosis intervention study; F: Fenofibrate; FIELD: Fenofibrate and event loweing in diabettes; G: Gemfibrozil; HHS: Helsinki heart srudy; VA-HIT: Veterans affairs high-density lipoprotein intervention trial. [4] [5] [6] [7] study end. HDL-C levels were raised 5% initially but only 1.2% by study end; and the reduction in triglyceride levels fell from an initial 29% reduction to a 22% reduction at study end. This probably reflects discontinuations of study drug and nonadherence. Surprisingly, however, the effect of the statin therapy initiation during the course of the study, which would have been expected to lower total and LDL-C further, does not appear to have occurred. Perhaps this means that patients discontinued the statin therapy soon after starting it, but the FIELD report provides no information on adherence to these other therapies. Compared with the lipid s reported in other fibrate outcome trials (Table 2), the s in the FIELD trial were inferior. The results in the diabetes atherosclerosis intervention study (DIAS), a small angiographic study utilizing fenofibrate 200 mg/day, report superior effects [2]. The difference in lipid s were also especially evident in the two studies employing gemfibrozil 1200 mg/day, the Helsinki Heart Study (HHS) [3], VA-HIT [4], and the one study employing bezafibrate 400 mg/day [5], especially with regard to HDL-C and triglyceride levels. Based on the relationship between decrements in LDL-C and CHD events observed in epidemiological trials and now affirmed by the statin, bile acid sequestrant and ileal bypass outcome trials, one would expect an approximate 1% reduction in coronary events for every 1% lowering in LDL-C. Additionally, based on epidemiological trials and affirmed by the two gemfibrozil outcome trials [3 4], one would expect a 1 2% reduction in CHD events for approximately every 1% increase in HDL-C. Based on this formula, the approximate reduction in major CHD events in FIELD would be predicted to be 16 22%, based on 4-months of lipid data and 8 9% based on study end data. The actual result was a reduction of 11% which probably reflects more precisely the mean lipid s over the course of the study. Table 2 also illustrates that significant reductions in major CHD events (CHD death and nonfatal MI) was obtained only in the two gemfibrozil studies (HHS [3] and VA-HIT [4]) and one of the two clofibrate studies [6]. In three of the fibrate outcome studies, a post hoc analysis showed that CHD event reduction was accentuated and reached significance in the subpopulation of study patients with high triglyceride and low HDL-C levels [5,8,9]. For example, in the HHS, a Table 3. Mortality with fibrate therapy. Fibrate studies (n = 17) Risk ratio (95% CI) Effect on total mortality 1.00 ( ) Effect on cardiac mortality 0.93 ( ) Effect on non-cv 1.13 ( ) mortality CI: Confidence interval; CV: Cardiovascular
5 PRIORITY PAPER EVALUATION McKenney LDL-C/HDL-C ratio of greater than 5 and a triglyceride level of over 200 mg/dl defined the population receiving the greatest benefit from gemfibrozil, a 75% lowering in CHD events [8]. In the bezafibrate infarction prevention (BIP) trial, patients with a HDL-C less than 35 mg/dl and a triglyceride level of 200 mg/dl or greater achieved the greatest reduction with bezafibrate, a 42% significant reduction in major CHD events [5]. In fact, these observations suggest that fibrates should be used and studied in patients with high triglyceride/low HDL-C syndromes. However, as revealed in Table 2, rarely have mean triglyceride levels been over 200 mg/dl (defined as high by National Cholesterol Education Program s Adult Treatment Panel [NCEP ATP III]) in any of the fibrate outcome trials. Conversely, LDL-C levels are frequently as high as those found in statin trials; this was the case in FIELD as triglyceride levels were barely in the borderline high range. Perhaps it is not so surprising that total CV events in FIELD were no different in patients with triglyceride levels above or below 150 mg/dl (3.7 mmol/l). The most disturbing result of FIELD was the increase in total, CV and CHD mortality. While this increase was not statistically significant, the trend was clearly in the wrong direction. FIELD is not alone in this regard. As seen in Table 2, increases in total and/or CHD mortality were also reported in the HHS with gemfibrozil [3], in the BIP study with bezafibrate [5] and in the WHO study with clofibrate [6], thus raising the question of whether this may be a class effect. This observation was strengthened further by a recent meta-analysis of 17 fibrate trials all containing a control group, using random allocation to treatment arms and continuing for at least 6 months [10]. The results show that fibrate therapy had a negligible effect on total mortality (i.e., no reduction) and a significant 13% increase in noncv mortality (Table 3) [10]. These observations alone require more study before fenofibrate or other fibrates are used widely. Managing coronary heart disease risk in patients with Type 2 diabetes Without question, based on the evidence, statins are the drug of choice for the management of CHD risk in patients with Type 2 diabetes mellitus (Table 4). They provide superior reduction in CHD and stroke risk. Recently, in the collaborative atorvastatin in diabetes study (CARDS), treatment of 2838 patients with Type 2 diabetes with atrovastatin 10 mg/day for 3.9 years was shown to reduce CHD death and nonfatal MI by 37% (p = 0.001); acute coronary syndromes by 36%; coronary revascularizations by 31%; strokes by 48% and death from any cause by 27% (p = 0.059) [12]. In a prespecified analysis, treatment of 5963 diabetic patients in the large HPS with simvastatin 40 mg/day for 5 years was associated with a 27% reduction in CHD death and nonfatal myocardial infarction (p = ), 24% reduction in strokes (p = 0.01) and a 17% reduction in revascularization procedures (p = 0.02) [11]. No information is provided on mortality outcomes. Two of four other large statin outcome trials reported a significant reduction in CHD events in diabetic cohorts per post hoc analyses (Table 4). There are far fewer outcome studies in Type 2 diabetes patients evaluating fibrate treatment. In the largest study of its kind in diabetic patients, FIELD failed to demonstrate significant reductions in CHD death and nonfatal MI or in mortality rates, although it did show reductions in nonfatal MI and revascularization procedures (Table 1) [1]. The VA-HIT substudy, in which male diabetic subjects with a prior CHD history and HDL-C lower than 40 mg/dl (l.0 mmol/l), were treated with gemfibrozil 1200 mg/day for 5 years, reported a significant 32% reduction in CHD events (p = 0.004), a 41% reduction in CHD death (p = 0.02) and a 40% reduction in stroke (p = 0.046) (Table 4) [14]. Therefore these results stand in contrast to the FIELD study results. Part of the explanation for this may be the high CHD risk present in the VA-HIT subjects, due mainly to the inclusion of exclusively male subjects with low HDL-C levels and prior CHD. FIELD included approximately 40% women and patients mostly with no prior CHD history (80%) who were selected mostly on the basis of high cholesterol levels. A recent evaluation of pioglitazone mg/day in 5238 patients with Type 2 diabetes (43% of whom were taking a statin) in the PROactive study reported a nonsignificant reduction in the primary composite end point and a weakly significant 16% reduction (p = 0.027) in the composite end point of total mortality, nonfatal MI and stokes (Table 4) [13]. These data support the NCEP ATP III recommendations for managing CHD risk in patients with Type 2 diabetes [19]. Due to their high near term and lifetime risk of CHD events, they were identified as a CHD risk equivalent by 278 Future Lipidol. (2006) 1(3)
6 When it comes to the FIELD study, what is...is PRIORITY PAPER EVALUATION Table 4. Outcome studies in patients with Type 2 diabetes mellitus. Study N Rx T. Chol LDL-C HLD-C TG Placebo CHD event rate (%) Placebo CV event rate (%) CHD risk* reduction Ref. FIELD 9795 F % (p = 0.16) HPS-DM 5963 S % (p <0.0001) CARDS 2838 A % (p = 0.001) PROactive 5238 Pio % (p = 0.027) VA-HIT 769 G NR % (DM) (p = 0.004) ASCOT 2532 A NR -16% (p = 0.43) 4S 483 S NR -42% p = 0.001) CARE 586 P % (p = 0.05) LIPID 1077 P % (p = 0.11) [1] [11] [12] [13] [14] [15] [16] [17] [18] *CHD death, nonfatal MI, CHD death, nonfatal MI, strokes. A: Atorvstatin; ASCOT: Anglo-Scandinavian cardiac outcomes trial; CARDS: Collaborative atorvastatin in diabetes study; CARE: Cholesterol and recurrent events; CHD: Coronary heart disease; Chol: Cholesterol; CV: Cardiovascular; F: Fenofibrate; FIELD: Fenofibrate and event loweing in diabettes; G: Gemfibrozil; HDL-C: High-density lipoprotein cholesterol; HPS-DM: Heart protection study in diabetics; LDL-C: Low-density lipoprotein cholesterol; P: Pravastatin; Pio: Pioglitazone; S: Simvastatin; TG: Triglyceride; VA-HIT: Veterans affairs high-density lipoprotein intervention trial. ATP III, which means that simply being a diabetic patient even without evidence of CHD is alone sufficient to be considered high risk and treated with the same intensity as if they had experienced a coronary event. The treatment goal for these patients is an LDL-C under 100 mg/dl (2.58 mmol/l). However, as HPS has taught us, high risk patients, including those with diabetes, who have an untreated LDL-C under 100 mg/dl benefit from statin therapy [20]. Therefore, NCEP ATP III recommends the option of treating diabetic patients to a LDL cholesterol goal of under 100 mg/dl or if their baseline LDL-C is under 100 mg/dl, lowering the LDL-C by at least 30 40%. Should the diabetic patient also have evidence of atherosclerotic vascular disease, multiple CHD risk factors (especially smoking), or the metabolic syndrome, NCEP recommends that a more aggressive LDL-C goal of under 70 mg/dl may be considered. As supported by the evidence, these goals are best achieved by a statin with sufficient LDL-C lowering efficacy to achieve these treatment goals and, for those already under 100 mg/dl, sufficient efficacy to produce a minimal 30 40% reduction, preferably more. For patients who do not achieve LDL-C goals with statin monotherapy, combination therapy is an option. Thus, the addition of other LDL-C lowering drugs to the statin, such as a bile acid sequestrant, cholesterol absorption inhibitor, or niacin may be considered. For patients who achieve their LDL-C goal but have a triglyceride over 200 mg/dl, the NCEP ATP III recommends that a second goal be established that is defined by non-hdl-c and set 30 mg/dl higher than the LDL-C goal [19]. These patients often have high very low-denisty lipoprotein (VLDL) remnant cholesterol levels, small dense LDL particles, low HDL-C, and high particle concentration/number. Here is where therapy with a fibrate or niacin is preferred. Not only can these products add to the LDL-C lowering of the statin (niacin generally more than fibrates) but they can also help lower non-hdl and remnant cholesterol levels, shift small dense LDL to larger particles, raise HDL-C levels and help reduce particle numbers. Since this is how fibrates are most often indicated for use in the clinical setting, it is also the context in which they should be evaluated in outcome studies. Thus, an improved design for FIELD would have been the 279
7 PRIORITY PAPER EVALUATION McKenney addition of randomly assigned fenofibrate or placebo to ongoing stable statin therapy for all study patients. Furthermore, the study should be conducted only in patients who have an elevated triglyceride level (and optionally also a low HDL-C level). This is really where those who constructed the FIELD study failed. It was not designed to address the clinically relevant question: does the addition of fenofibrate on a background of statin therapy in high-risk diabetic patients with high triglyerides add CHD risk reduction? It really is a shame to have spent so much time and money conducting such a flawed study. Fortunately, a study is underway in the USA and Canada to help address this critical clinical question. The action to control cardiovascular risk in diabetes (ACCORD) study, sponsored by the US National Heart, Lung and Blood Institute, intends to enroll 10,000 patients with Type 2 diabetes and hypertension or dyslipidemia who will be followed for years. Patients who have elevated LDL-C and triglycerides and a low HDL-C will receive a less intense treatment with simvastatin 20 mg/day versus a more intense treatment with simvastatin 20 mg/day plus a fibrate. The primary end point will be nonfatal MI, nonfatal stroke and CV death. The study is scheduled to be completed by Until the results of ACCORD are available, only weak evidence-based justification exists to begin or continue fenofibrate therapy for CHD risk reduction. Fenofibrate is still useful as a triglyceride lowering treatment for patients with very high triglyceride levels (> 500 mg/dl or 12.9 mmol/l). Gemfibrozil has stronger support from randomized clinical outcome trials, but presents a significant drug interaction problem in combination with a statin. Niacin also has stronger support mainly from the CDP [7], which demonstrated CHD risk reduction in the 5-year trial and a mortality reduction 10 years after the trial was ended. Unfortunately for fenofibrate and the FIELD study, this is what is, at least for the moment. Disclosure James M McKenney, Pharm.D. is a member of the Speakers Bureau for AstraZeneca, KOS Pharmaceuticals, Merck & Co., Pfizer Inc., Reliant Pharmaceuticals, Schering-Plough and Takeda; serves as a consultant to AstraZeneca, KOS Pharmaceuticals, Microbia, Pfizer Inc., and Sankyo Pharma; and has received research grant support from AstraZeneca, GlaxoSmithKline, KOS Pharmaceuticals, Merck & Co., Reliant Pharmaceuticals, F. Hoffmann-La Roche Pharmaceuticals, Pfizer Inc., Schering-Plough and Takeda. Bibliography 1. The FIELD Investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, (2005). 2. Diabetes Atherosclerosis Intervention Study Investigators: Effect of fenofibrate on progression on coronary-artery disease in Type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357, (2001). 3. Frick MH, Elo O, Haapa K et al.: Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-age men with dyslipidemia. Safety of treatment, s in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317, (1987). 4. Rubins HB, Sander JR, Collins D et al. for the Veteran Affairs High Density Lipoprotein Cholesterol Intervention Trial Study Group: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N. Engl. J. Med. 341, (1999). 5. The BIP study group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 102, (2000). 6. Report from the Committee of Principal Investigators: A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br. Heart J. 40, (1978). 7. The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 231, (1975). 8. Manninen V, Tenkanen L, Koskinen P et al.: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85, (1992). 9. Robins SJ, Collins D, Wittes JT et al. for the VA-HIT Study Group: Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial. JAMA 285, (2001). 10. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC: Effects of different antilipidemic agents and diets on mortality. A systematic review. Arch. Intern. Med. 165, (2005). 11. Heart Protection Study Collaborative Group: MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 361, (2003). 12. Colhoun HM, Betteridge DJ, Durrington PN et al. on behalf of the CARDS investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364, (2004). 13. Dormandy JA, Charbonnel B, Eckland DJA et al. on behalf of the PROactive investigators: Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial in macrovascular Events): a randomised controlled trial. Lancet 366, (2005). 14. Rubins HB, Robins SJ, Collins D et al. for the VA-HIT Study Group: Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch. Intern. Med. 162, (2002). 280 Future Lipidol. (2006) 1(3)
8 When it comes to the FIELD study, what is...is PRIORITY PAPER EVALUATION 15. Sever PS, Dahlof B, Poulter NR et al. for the ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, (2003). 16. Haffner SM, Alexander CM, Cook TJ et al. for the Scandinavian Simvastatin Study Group: Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch. Intern. Med. 159, (1999). 17. Keech A, Colquhoun D, Best J et al.: For the LIPID study group: Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose. Diabetes Care 26, (2003). 18. Goldberg RB, Mellies MJ, Sacks FM et al. for the CARE investigators: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 98, (1998). 19. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, (2002). 20. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360, 7 22 (2002). Affiliation James M McKenney Virginia Commonwealth University, National Clinical Research, 2809 Emerywood Parkway, Suite 140, Richmond, VA 23294, USA Tel.: ; Fax: ; jmckenney@ncrinc.net 281
( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationThe American Diabetes Association estimates
DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationStatins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. C ANYANWU, C NOSIRI Citation C ANYANWU, C NOSIRI.
More informationAPPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationLIST OF ABBREVIATIONS
Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,
More informationComparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients
Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients Cardiology Department, Bangkok Metropolitan Medical College and Vajira Hospital, Bangkok, Thailand Abstract
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationUse of Subgroups to Rescue a Trial or Improve Benefit-Risk
1 Use of Subgroups to Rescue a Trial or Improve Benefit-Risk Martin King, Ph.D. Director, Statistics Global Pharmaceutical R&D, Abbott Abbott Park, IL USA 2 Disclaimer The opinions in this presentation
More informationHyperlipidemia and Cardiovascular Disease. Kathmandu November 2010 Harold E. Lebovitz, MD, FACE
Hyperlipidemia and Cardiovascular Disease Kathmandu November 21 Harold E. Lebovitz, MD, FACE Diabetes and Lifetime Risk for CHD Adjusted cummula ative incidence.7.6.5 Men 67% 3%.7.6.5 Women Diabetes No
More informationMedical evidence suggests that
COMBINATION THERAPY TO ACHIEVE LIPID GOALS David G. Robertson, MD* ABSTRACT Coronary heart disease (CHD) remains the leading cause of death in the United States despite recent advances in treatment and
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationChanging lipid-lowering guidelines: whom to treat and how low to go
European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationGUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES
GUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES Prepared by DCPNS Action Committee Dr. Lynne Harrigan Brenda Cook Peggy Dunbar Bev Harpell with the assistance
More informationEFFECT OF GOOD GLYCEMIC CONTROL ON LIPID PROFILE IN TYPE 2 DIABETES MELLITUS PATIENTS IN AL HUSSEIN TEACHING HOSPITAL
Thi-Qar Medical Journal (TQMJ): Vol(5) No(2):2011(39-44) EFFECT OF GOOD GLYCEMIC CONTROL ON LIPID PROFILE IN TYPE 2 DIABETES MELLITUS PATIENTS IN AL HUSSEIN TEACHING HOSPITAL Dr. Akeel bal-yaqobi *, Dr.
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationFibrates. Spotlight on. Fibric acid derivatives (fibrates) have been used. When should I prescribe fibrates? In this article: Andrew s visit
Focus on CME at the University of Alberta Spotlight on By T. K. Lee, MSc (Exp. Medicine), MB, BS, MRCP(UK), ABIM, FRCPC As presented at the Drug Update & Practical Therapeutics Course, November 8, 2002.
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More informationThe role of statins in patients with arterial hypertension
Invited review The role of statins in patients with arterial hypertension Trygve B. Tjugen 1, Sigrun Halvorsen 1, Reidar Bjørnerheim 1, Sverre E. Kjeldsen 1, 2 1University of Oslo, Department of Cardiology,
More informationData Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association
More informationLow HDL and Diabetic Dyslipidemia
The Lowdown: Low HDL and Diabetic Dyslipidemia Patients with diabetes commonly have a low-density lipoprotein cholesterol (LDL-C) no higher than that of the general population. What treatment is warranted
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationnicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck
Scottish Medicines Consortium Resubmission nicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck New formulation 6 January 2006 The Scottish Medicines Consortium
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationManagement of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil
Management of LDL as a Risk Factor Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Consulting for: Merck, Astra Zeneca, ISIS- Genzyme, Novo-Nordisk, BMS, Pfizer,
More informationStatins in the elderly : Is there a rationale?
Statins in the elderly : Is there a rationale? Pr B Boland After a communication by Dr. Manfred Gogol EAMA, Sion, June, 2006 1 RCTs with Statins Meta-Analysis, 1999 182 abstracts or research papers 29
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationRECOGNITION OF THE METABOLIC SYNDROME
THE METABOLIC SYNDROME IN CLINICAL PRACTICE Michael H. Davidson, MD* ABSTRACT Patients with the metabolic syndrome remain at significantly elevated risk of morbidity and mortality associated with coronary
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationAdvances in Lipid Management
Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center
More information... CPE/CNE QUIZ... CPE/CNE QUESTIONS
CPE/CNE QUESTIONS Continuing Pharmacy Education Accreditation The Virginia Council on Pharmaceutical Education is approved by the American Council on Pharmaceutical Education as a provider of continuing
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationReducing low-density lipoprotein cholesterol treating to target and meeting new European goals
European Heart Journal Supplements (2004) 6 (Supplement A), A12 A18 Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals University of Sydney, Sydney, NSW, Australia
More informationThe All Wales Medicine Strategy Group (AWMSG) is asked to support implementation of the following prescribing indicators.
ENCLOSURE 5 APPENDIX 1 Paper presented to AWMSG in June 2006 AWPAG considered comments recorded in AWMSG minutes in July 2006 Paper subsequently updated and brought back to AWMSG for endorsement This paper
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationNearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III
... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III Robert L. Talbert, PharmD Abstract Coronary heart disease (CHD) is a common, costly, and undertreated
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationCholesterol lowering intervention for cardiovascular prevention in high risk patients with or without LDL cholesterol elevation
TrialResults-center.org www.trialresultscenter.org Cholesterol lowering intervention for cardiovascular prevention in high risk patients with or without LDL cholesterol elevation A systematic review and
More informationLipid Management: Beyond LDL
Lipid Management: Beyond LDL Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine University of Kentucky Overview Discuss the concept of residual risk Review current evidence-based medicine
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationNCEP Report. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
NCEP Report Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Scott M. Grundy; James I. Cleeman; C. Noel Bairey Merz; H. Bryan Brewer,
More informationModern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
More informationSupplementary Online Content
Supplementary Online Content Gutierrez J, Ramirez G, Rundek T, Sacco RL. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med. 2012;172(12):IRA120005.
More informationDyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III
More informationSupplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction
Supplement: Tables Supplement Table 1. Study Eligibility Criteria Supplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction Supplement Table
More informationLessons from Recent Atherosclerosis Trials
Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD
More informationTreating Lipids for Prevention of CAD in Women: Matching Therapy to Risk
TREATING LIPIDS FOR PREVENTION OF CAD IN WOMEN: MATCHING THERAPY TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationCoronary artery disease remains the leading
UNMET NEEDS IN THE TREATMENT OF ATHEROSCLEROSIS: WHY ARE WE NOT DONE YET? * Evan A. Stein, MD, PhD ABSTRACT Heart disease remains the leading cause of death in the United States. Despite advances in surgical,
More informationNon-Statin Lipid-Lowering Agents M Holler - Last updated: 10/2016
Drug/Class Cholestyramine (Questran) Bile acid sequestrant Generic? Lipid Effects Y/N (monotherapy) Y LDL : 9% (4 g to 8 ; 21% (16 g to 20 ; 23% to 28% (>20 HDL : 4% to 8% (16 to 24 TG : 11% to 28% (4
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationThe Target is LDL, HDL not so much
The Target is LDL, HDL not so much HDL: A riddle wrapped in a mystery inside an enigma Jacques Genest MD Cardiovascular Research Laboratories McGill University Health Center Disclosure J. Genest MD 2013
More informationOn May 2001, the Third Adult
THE RISK OF DIABETES: CAN WE IMPACT CHD THROUGH THE ATP III CHOLESTEROL GUIDELINES? * Based on a presentation given by Steven M. Haffner, MD, MPH ABSTRACT Diabetes has been recognized among diabetologists
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationThe Metabolic Syndrome
The Metabolic Syndrome Advances in Internal Medicine David D. Waters, MD May 21, 27 UCSF Metabolic Syndrome: Definition abdominal obesity increased waist circumference atherogenic dyslipidemia low HDL-C,
More informationAIM HIGH for SATURN and stay SHARP; COURAGE (v1.5)
AIM HIGH for SATURN and stay SHARP; COURAGE (v1.5) Jacques Genest MD Cardiovascular Research Laboratory McGill University Health Center Disclosure J. Genest MD 2012 Advisory Board, Speaker s Bureau, Consultant,
More informationAttainment of Combined Optimal Lipid Values With the Use of Niacin
www.medscape.com Attainment of Combined Optimal Lipid Values With the Use of Niacin Has AIM-HIGH Closed the Book on This Debate? Tyan Thomas Clin Lipidology. 2012;7(4):389-396. Abstract and Introduction
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationLipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of:
Lipid Management: A Case-Based Approach Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationNew Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines
Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationSOLVAY GROUP London Morning Meeting. June 26, 2009
SOLVAY GROUP London Morning Meeting June 2, 9 1 Our fenofibrate franchise Klaus Kirchgassler, MD Sr VP Solvay Pharmaceuticals 2 Summary of lipid lowering market performance in Value Growth vs. previous
More informationSTATINS FOR PAD Long - term prognosis
STATINS FOR PAD Long - term prognosis Prof. Pavel Poredos, MD, PhD Department of Vascular Disease University Medical Centre Ljubljana Slovenia DECLARATION OF CONFLICT OF INTEREST No conflict of interest
More informationDiabetes mellitus is a leading cause of morbidity and
Clinical Guidelines Lipid Control in the Management of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians Vincenza Snow, MD; Mark D. Aronson, MD; E. Rodney
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationMS Sabatine, RP Giugliano, AC Keech, PS Sever, SA Murphy and TR Pedersen, for the FOURIER Steering Committee & Investigators
Evolocumab Reduces Cardiovascular Events in Patients with Baseline LDL-C
More informationThe Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4)
The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4) Denis Xavier MD, MSc Professor and Head, Pharmacology, St. John's Medical College Coordinator, Division
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationAlthough medical advances have curbed
PREVENTION OF CORONARY HEART DISEASE IN THE METABOLIC SYNDROME AND DIABETES MELLITUS * Sherita Hill Golden, MD, MHS ABSTRACT The leading cause of death in patients with diabetes is cardiovascular disease.
More informationPresenter Disclosure Information
1:45 2:45pm Lipid Management: A Primary Care Perspective Presenter Disclosure Information The following relationships exist related to this presentation: Richard F. Wright, MD, FACC, has no financial relationships
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationIn the Know: Canadian Guidelines for Dyslipidemia, 2003
In the Know: Canadian Guidelines for Dyslipidemia, 2003 In his reviews of Canadian dyslipidemia guidelines, Dr. Curnew explores the impact of major trials, the assessment and categories of risk, and both
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationThe new guidelines issued in PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice
... PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice Based on a presentation by Daniel J. Rader, MD Presentation Summary The guidelines recently released by the National Cholesterol
More informationDecline in CV-Mortality
Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer
More informationFelix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study
Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee
More information